A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus
Abstract
Seasonal influenza infection remains a major cause of disease and death, underscoring the need for improved vaccines. Among current influenza vaccines, the live attenuated influenza vaccine (LAIV) is unique in its ability to elicit T-cell immunity to the conserved internal proteins of the virus. Despite this, LAIV has shown limited efficacy in recent years. One possible reason is that the conserved, internal genes of all current LAIVs derive from virus strains that were isolated between 1957 and 1960 and that, as a result, do not resemble currently circulating influenza viruses. We have therefore developed and tested a new LAIV, based on a currently circulating pandemic strain of influenza. Our results show that this new LAIV elicits improved protective immunity compared to a more conventional LAIV.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 31, 2020
- Source ID
- 10.1128/jvi.01065-19
Entities
People
- Aitor Nogales
- Andrew N. Smith
- Changyong Feng
- David J Topham
- Emma Reilly
- Jeffrey M. Chamberlain
- Katherine Sortino
- Laura Rodriguez
- Luis Martinez-Sobrido
- Maya El Ghouayel
- Stephen Dewhurst
Organizations
- National Institutes of Health
- United States Department of Defense
- University of Rochester